Is CCEP a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Coca-Cola Europacific Partners (CCEP) rests on Asia Pacific scale, with the Philippines as the swing factor: Australia, New Zealand, Indonesia, Papua New Guinea, Fiji and now the Philippines give CCEP a growth engine that a purely European bottler would lack. The bear case rests on currency is the first thing a US shareholder should understand: CCEP reports in euros while the Nasdaq line quotes in dollars, so a weaker euro compresses reported dollar returns even when the underlying business is fine, and the group also carries Australian dollar, sterling, rupiah and peso translation exposure. Analysts covering it publish targets from $91.52 to $128.65 against a $119.19 share price on November 16, 2026, so even the professionals disagree by 32% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
CCEP key stats
At $119.19 on November 16, 2026, Coca-Cola Europacific Partners (CCEP) has a market cap of $52.3B, a P/E of 23.0 on trailing earnings (21.5 on forward earnings) and a dividend yield of 2.02%.
- Market cap
- $52.3B
- P/E (trailing)
- 23.0
- P/E (forward)
- 21.5
- EPS (trailing 12 months)
- $5.18
- Price to book
- 5.7
- Dividend yield
- 2.02%
- Beta
- 0.46
Market cap, P/E and yield are measured at the $119.19 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Coca-Cola Europacific Partners (CCEP)?
The last two weeks for Coca-Cola Europacific Partners, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- CCEP closed at $119.19 on November 16, 2026, up 1.4% over the past five trading days (from $117.49).
- On November 16, 2026, Coca-Cola Europacific Partners filed a current report (6-K) with the SEC. Read the 6-K on sec.gov
- On November 5, 2026, Barclays raised its target to $124.00 from $112.00 (Overweight).
- On November 4, 2026, UBS raised its target to $115.00 from $107.00 (Neutral).
- On November 4, 2026, Wells Fargo raised its target to $120.00 from $115.00 (Overweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Coca-Cola Europacific Partners makes, packages, sells and delivers non-alcoholic ready-to-drink beverages under licence from The Coca-Cola Company and a handful of partner brand owners. Its portfolio spans Coca-Cola, Coca-Cola Zero Sugar, Fanta, Sprite, Schweppes, Monster Energy, Costa Coffee ready-to-drink, Powerade, Capri-Sun, Vitaminwater, Smartwater and, in Australia and the Pacific, the former Amatil brands. The territory list runs across Western Europe (Great Britain, Germany, Spain, France, Belgium, the Netherlands, Portugal, Norway, Sweden, Iceland and smaller markets) plus an Asia Pacific segment built from the 2021 acquisition of Coca-Cola Amatil, which brought Australia, New Zealand, Indonesia, Papua New Guinea and Fiji, and the 2024 purchase of a 60% stake in Coca-Cola Beverages Philippines alongside Aboitiz Equity Ventures. Around ~37,000 employees run the plants, warehouses and route-to-market fleets that reach several hundred million consumers. Ownership is concentrated: Olive Partners, tied to the Daurella family, holds roughly ~36%, and The Coca-Cola Company itself holds roughly ~17%. The investment picture is a franchised, capital-intensive staples business with better arithmetic than most bottlers get credit for. Trailing revenue of ~EUR 21.4bn converts at roughly ~$24.4bn, operating margin sits near ~13.5%, return on equity near ~23.5%, and Yahoo Finance puts trailing free cash flow at about ~1.6bn against operating cash flow of ~3.0bn. First-half 2026 revenue of ~EUR 10.7bn grew ~4.4% as reported and ~6.1% currency-neutral, with operating profit of ~EUR 1.48bn up ~8.1% currency-neutral, and management reaffirmed full-year guidance of ~3% to 4% revenue growth, roughly ~7% operating profit growth and comparable free cash flow of at least ~EUR 1.7bn. Capital returns are explicit: an interim dividend of ~EUR 0.82 per share, a payout policy around ~50% of comparable earnings, and a ~EUR 1bn buyback that was about ~EUR 593m complete by the end of July 2026. Against that, the stock trades near ~21.7x trailing and ~20.4x forward earnings with ~12.2bn of gross debt, a persistent valuation gap to KO that reflects exactly what a bottler is: the party carrying the trucks, the plants and the packaging regulation. Since the half-year results the shares have kept climbing. As of the 16 October 2026 close of ~$112.29 they were up about ~27% year to date and ~26% over one year, close to the 52-week high of ~$113.67 and above the analysts' mean target of ~$109.68 (12 analysts, consensus rating buy). Recent commentary is mixed rather than one-sided: in early October UBS said CCEP was likely to post a Q3 organic sales beat, while Jefferies argued European soft drinks growth is slowing as volumes normalise. Consensus looks for Q3 revenue of about ~5.67bn, and full-year 2026 revenue of ~21.6bn rising to ~22.5bn in 2027.
The bull case: what would have to be true for $128.65
The most optimistic published target on CCEP is $128.65, +7.9% from the $119.19 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Asia Pacific scale, with the Philippines as the swing factor
Australia, New Zealand, Indonesia, Papua New Guinea, Fiji and now the Philippines give CCEP a growth engine that a purely European bottler would lack. Coca-Cola Beverages Philippines came in at a $1.8bn enterprise valuation in a 60:40 structure with Aboitiz Equity Ventures, and the value case rests on lifting a large, underpenetrated market toward CCEP's own operating standards. Execution here is where the difference between a mid-single-digit and a high-single-digit grower gets decided.
2. Revenue growth management rather than volume heroics
Most of CCEP's top-line progress comes from price, pack architecture and mix rather than raw litres, which is the standard playbook for a mature European staples business. Small immediate-consumption packs, single-serve chilled placements and premium formats carry far better revenue per litre than multipack take-home. First-half 2026 delivered ~6.1% currency-neutral revenue growth against far more modest volume, which is that mechanism working. Jefferies' October 2026 view that European soft drinks volumes are normalising puts more weight on this pricing and mix lever for the rest of the year, while UBS expects a Q3 organic sales beat.
3. Portfolio mix shifting toward zero sugar, energy and coffee
Coca-Cola Zero Sugar has been the fastest-growing part of the core cola franchise, and CCEP also distributes Monster Energy across its territories plus Costa Coffee ready-to-drink. Energy and zero-sugar formats carry higher margins and sidestep the sugar-tax exposure that hits full-sugar sparkling drinks. Mix shift of this kind compounds quietly and shows up in gross margin rather than in headline volume.
4. Cash conversion funding a dividend and a running buyback
Guidance calls for at least ~EUR 1.7bn of comparable free cash flow in 2026, against a stated payout target near ~50% of comparable earnings and a ~EUR 1bn repurchase programme roughly ~EUR 593m complete by 31 July 2026. Yahoo Finance shows trailing free cash flow of about ~1.6bn on ~3.0bn of operating cash flow, which is a reminder that bottling is capital-hungry, so the durability of that cash conversion is the number that matters most to a long-term holder. Deleveraging after the Amatil and Philippines deals competes directly with buybacks for the same euros.
The bear case: what would have to be true for $91.52
The most pessimistic published target is $91.52, -23.2% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Coca-Cola Europacific Partners is worth if the risks below bite instead of the drivers above.
Currency is the first thing a US shareholder should understand: CCEP reports in euros while the Nasdaq line quotes in dollars, so a weaker euro compresses reported dollar returns even when the underlying business is fine, and the group also carries Australian dollar, sterling, rupiah and peso translation exposure. Leverage is real, with roughly ~12.2bn of gross debt against ~2.0bn of cash and a debt-to-equity ratio near ~1.39, a legacy of financing the Amatil and Philippines acquisitions. Regulation is a standing headwind rather than an event: sugar levies across the UK, Ireland, Spain, Portugal and elsewhere, extended producer responsibility fees on packaging, deposit return schemes and the EU Packaging and Packaging Waste Regulation all raise the cost of putting a drink on a shelf. The whole business also depends on bottling and distribution agreements with The Coca-Cola Company, which owns roughly ~17% of CCEP and sets concentrate pricing, so the economics are negotiated rather than sovereign. Product-quality events can be expensive and public, as in January 2025 when CCEP recalled Coca-Cola and related products produced at its Ghent plant across Belgium, the Netherlands, Luxembourg, France, Germany and Great Britain after elevated chlorate levels were detected. Valuation is now a risk in its own right: after a ~27% rise in 2026 the shares trade above the ~$109.68 mean analyst target, so a softer Q3 or a volume slowdown of the kind Jefferies flagged in October could weigh on the multiple. As of August 2026 no active US securities-fraud class action against CCEP was identified, and the company filed its FY2025 Form 20-F in March 2026 with continuing routine 6-K filings, with no Form 25 or delisting process in evidence. Walnut is not an investment adviser; this page describes the business and is not a recommendation.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CCEP already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on CCEP
12 analysts cover CCEP, with an average target of $114.68 (-3.8% against $119.19) and a split of 8 buy, 3 hold, 2 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CCEP forecast and price target page.
How is CCEP valued?
Market cap, P/E and dividend yield at today's price are in the CCEP key stats above. The business figures below come from Coca-Cola Europacific Partners's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~EUR 21.4bn (latest qtr ~4.4% YoY)
- Operating / net margin (TTM): ~13.4% / ~9.4%
- Free cash flow / operating cash flow (TTM): ~1.6bn / ~3.0bn
As of October 2026: Reported figures are in euros while the Nasdaq line quotes in dollars, so headline conversions move with the exchange rate rather than with trading. After a ~27% year-to-date rise to ~$112.29 on 16 October 2026, CCEP trades at about ~21.7x trailing and ~20.4x forward earnings, slightly above the ~$109.68 mean analyst target, though still at a discount to The Coca-Cola Company. A payout ratio under half of earnings and a ~2.2% yield keep the defensive character, with the Q3 trading update the next datapoint.
How do you decide if CCEP is a buy?
Whether CCEP is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CCEP indirectly through an index or sector ETF before adding more.
What would change your mind on CCEP
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Asia Pacific scale, with the Philippines as the swing factor stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: currency is the first thing a US shareholder should understand: CCEP reports in euros while the Nasdaq line quotes in dollars, so a weaker euro compresses reported dollar returns even when the underlying business is fine, and the group also carries Australian dollar, sterling, rupiah and peso translation exposure fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the CCEP stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CCEP against your real portfolio and see your actual exposure before deciding.
Your questions about Coca-Cola Europacific Partners
Ask Walnut's AI anything about CCEP and see how it fits what you own.
FAQ
Is CCEP a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Asia Pacific scale, with the Philippines as the swing factor, with revenue (ttm) at ~EUR 21.4bn (latest qtr ~4.4% YoY). The bear case rests on currency is the first thing a US shareholder should understand: CCEP reports in euros while the Nasdaq line quotes in dollars, so a weaker euro compresses reported dollar returns even when the underlying business is fine, and the group also carries Australian dollar, sterling, rupiah and peso translation exposure. Analysts covering it are spread from $91.52 to $128.65, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell CCEP?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Currency is the first thing a US shareholder should understand: CCEP reports in euros while the Nasdaq line quotes in dollars, so a weaker euro compresses reported dollar returns even when the underlying business is fine, and the group also carries Australian dollar, sterling, rupiah and peso translation exposure. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $91.52, -23.2% from the $119.19 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for CCEP?
+
Asia Pacific scale, with the Philippines as the swing factor. Australia, New Zealand, Indonesia, Papua New Guinea, Fiji and now the Philippines give CCEP a growth engine that a purely European bottler would lack. The most optimistic analyst target on CCEP is $128.65, +7.9% from the $119.19 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for CCEP?
+
Currency is the first thing a US shareholder should understand: CCEP reports in euros while the Nasdaq line quotes in dollars, so a weaker euro compresses reported dollar returns even when the underlying business is fine, and the group also carries Australian dollar, sterling, rupiah and peso translation exposure. Leverage is real, with roughly ~12.2bn of gross debt against ~2.0bn of cash and a debt-to-equity ratio near ~1.39, a legacy of financing the Amatil and Philippines acquisitions. Regulation is a standing headwind rather than an event: sugar levies across the UK, Ireland, Spain, Portugal and elsewhere, extended producer responsibility fees on packaging, deposit return schemes and the EU Packaging and Packaging Waste Regulation all raise the cost of putting a drink on a shelf. The whole business also depends on bottling and distribution agreements with The Coca-Cola Company, which owns roughly ~17% of CCEP and sets concentrate pricing, so the economics are negotiated rather than sovereign. Product-quality events can be expensive and public, as in January 2025 when CCEP recalled Coca-Cola and related products produced at its Ghent plant across Belgium, the Netherlands, Luxembourg, France, Germany and Great Britain after elevated chlorate levels were detected. Valuation is now a risk in its own right: after a ~27% rise in 2026 the shares trade above the ~$109.68 mean analyst target, so a softer Q3 or a volume slowdown of the kind Jefferies flagged in October could weigh on the multiple. As of August 2026 no active US securities-fraud class action against CCEP was identified, and the company filed its FY2025 Form 20-F in March 2026 with continuing routine 6-K filings, with no Form 25 or delisting process in evidence. Walnut is not an investment adviser; this page describes the business and is not a recommendation. The most pessimistic published target is $91.52, -23.2% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Coca-Cola Europacific Partners do?
+
Coca-Cola Europacific Partners makes, packages and delivers ready-to-drink beverages under licence from The Coca-Cola Company across Europe and Asia-Pacific.
What would have to change for CCEP to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Asia Pacific scale, with the Philippines as the swing factor) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (currency is the first thing a US shareholder should understand: CCEP reports in euros while the Nasdaq line quotes in dollars, so a weaker euro compresses reported dollar returns even when the underlying business is fine, and the group also carries Australian dollar, sterling, rupiah and peso translation exposure) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Coca-Cola Europacific Partners actually do?
+
It manufactures, packages, sells and delivers non-alcoholic drinks under licence from brand owners, principally The Coca-Cola Company. Concentrate arrives from the brand owner; CCEP adds water, sweetener and carbonation, fills bottles and cans, and runs the warehouses, trucks and sales force that get them into supermarkets, restaurants and vending machines across ~31 markets.
Is CCEP the same thing as The Coca-Cola Company (KO)?
+
No. KO owns the trademarks, sets the marketing and sells concentrate; CCEP is a separately listed bottler that buys that concentrate and does the physical work. KO holds roughly ~17% of CCEP, but they are distinct companies with different margins, different capital intensity and different valuations, with CCEP typically trading at a lower multiple.
Where is CCEP listed, and can a US investor hold it directly?
+
Its primary listing is on the Nasdaq Global Select Market under CCEP, with additional listings on Euronext Amsterdam, the London Stock Exchange and the Spanish exchanges. Because the Nasdaq line is an ordinary share listing rather than a thin ADR, it trades in US dollars through any standard US brokerage account during regular US market hours.
Walnut is informational, not investment advice, and gives no verdict on CCEP. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.